Companies › Shanghai Synvida Biotechnology
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Respiratory, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SV001 | – | Phase 2 | Idiopathic Pulmonary Fibrosis(IPF) | Dec 2026 |
| SV003 | – | Phase 1 | Healthy Participants | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07121413 | SV001 | Phase 2 | Idiopathic Pulmonary Fibrosis(IPF) | Respiratory | Dec 2026 |
| NCT07469085 | SV003 | Phase 1 | Healthy Participants | Other | Mar 2027 |
No annotated target.
–
Kymera Therapeutics Tortugas Neuroscience Shanghai Yidian Pharmaceutical Technology Development ReAlta Life Sciences Insmed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.